About: Arimoclomol

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Arimoclomol (INN; originally codenamed BRX-345, which is a citrate salt formulation of BRX-220) is an experimental drug developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. In 2011 the worldwide rights to arimoclomol were bought by Danish biotech company Orphazyme ApS. The European Medicines Agency (EMA) and U.S. Food & Drug Administration (FDA) granted orphan drug designation to arimoclomol as a potential treatment for Niemann-Pick type C in 2014 and 2015 respectively.

Property	Value
dbo:abstract	Arimoclomol (INN; originally codenamed BRX-345, which is a citrate salt formulation of BRX-220) is an experimental drug developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. In 2011 the worldwide rights to arimoclomol were bought by Danish biotech company Orphazyme ApS. The European Medicines Agency (EMA) and U.S. Food & Drug Administration (FDA) granted orphan drug designation to arimoclomol as a potential treatment for Niemann-Pick type C in 2014 and 2015 respectively. (en) Arimoclomol (INN; nome in codice BRX-345, è una formulazione di sale citrato di BRX-220), esso è un farmaco sperimentale sviluppato da , una società biofarmaceutica con sede a Los Angeles, California. Il farmaco somministrato per via orale è studiato per il trattamento la sclerosi laterale amiotrofica (SLA). (it)
dbo:casNumber	289893-25-0
dbo:chEMBL	2107726
dbo:fdaUniiCode	EUT3557RT5
dbo:kegg	D11374
dbo:pubchem	208924
dbo:thumbnail	wiki-commons:Special:FilePath/Arimoclomol.svg?width=300
dbo:wikiPageID	4802464 (xsd:integer)
dbo:wikiPageLength	9374 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1120547318 (xsd:integer)
dbo:wikiPageWikiLink	dbr:CytRx dbr:Insulin_resistance dbc:Piperidines dbr:Los_Angeles,_California dbr:Clinical_trial dbr:Heat_shock_protein dbc:3-Pyridyl_compounds dbc:Amine_oxides dbc:Drugs_acting_on_the_nervous_system dbr:European_Medicines_Agency dbr:Diabetic_nephropathy dbr:Diabetic_neuropathy dbr:International_Nonproprietary_Name dbr:Diabetic_retinopathy dbr:Hsp70 dbr:Chaperone_(protein) dbr:U.S._Food_&_Drug_Administration dbr:Niemann-Pick
dbp:atcPrefix	N07 (en)
dbp:atcSuffix	XX17 (en)
dbp:c	14 (xsd:integer)
dbp:casNumber	289893 (xsd:integer)
dbp:chembl	2107726 (xsd:integer)
dbp:chemspiderid	21106260 (xsd:integer)
dbp:cl	1 (xsd:integer)
dbp:h	20 (xsd:integer)
dbp:iupacName	N-{[-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide (en)
dbp:kegg	D11374 (en)
dbp:legalStatus	Investigational (en)
dbp:n	3 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	208924 (xsd:integer)
dbp:routesOfAdministration	Oral (en)
dbp:smiles	O[C@H]CO\N=Cc2ccc[n+]c2 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	SGEIEGAXKLMUIZ-ZPTIMJQQSA-N (en)
dbp:unii	EUT3557RT5 (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	447557873 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Other_nervous_system_drugs dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite
dcterms:subject	dbc:Piperidines dbc:3-Pyridyl_compounds dbc:Amine_oxides dbc:Drugs_acting_on_the_nervous_system
gold:hypernym	dbr:Drug
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 yago:WikicatDrugs umbel-rc:DrugProduct
rdfs:comment	Arimoclomol (INN; originally codenamed BRX-345, which is a citrate salt formulation of BRX-220) is an experimental drug developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. In 2011 the worldwide rights to arimoclomol were bought by Danish biotech company Orphazyme ApS. The European Medicines Agency (EMA) and U.S. Food & Drug Administration (FDA) granted orphan drug designation to arimoclomol as a potential treatment for Niemann-Pick type C in 2014 and 2015 respectively. (en) Arimoclomol (INN; nome in codice BRX-345, è una formulazione di sale citrato di BRX-220), esso è un farmaco sperimentale sviluppato da , una società biofarmaceutica con sede a Los Angeles, California. Il farmaco somministrato per via orale è studiato per il trattamento la sclerosi laterale amiotrofica (SLA). (it)
rdfs:label	Arimoclomol (en) Arimoclomol (it)
owl:sameAs	freebase:Arimoclomol yago-res:Arimoclomol wikidata:Arimoclomol dbpedia-it:Arimoclomol dbpedia-sh:Arimoclomol dbpedia-sr:Arimoclomol https://global.dbpedia.org/id/4SUVq
prov:wasDerivedFrom	wikipedia-en:Arimoclomol?oldid=1120547318&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Arimoclomol.svg
foaf:isPrimaryTopicOf	wikipedia-en:Arimoclomol
is dbo:wikiPageRedirects of	dbr:C14H20ClN3O3
is dbo:wikiPageWikiLink of	dbr:Amyotrophic_lateral_sclerosis_research dbr:Complete_Response_Letter dbr:C14H20ClN3O3 dbr:Niemann–Pick_disease dbr:Niemann–Pick_disease,_type_C dbr:ATC_code_N07
is foaf:primaryTopic of	wikipedia-en:Arimoclomol

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License